ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Portland, OR, USA:

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Portland, Oregon, United States and 164 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Portland, Oregon, United States and 23 other locations

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...

Enrolling
Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Gilteritinib

Phase 1, Phase 2

Astellas
Astellas

Portland, Oregon, United States and 18 other locations

and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allog...

Enrolling
ACUTE MYELOID LEUKEMIA; AML
MYELODYSPLASTIC SYNDROME; MDS
Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)

Phase 1

Jasper Therapeutics

Portland, Oregon, United States and 5 other locations

A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...

Enrolling
Acute Myeloid Leukemia (AML)
Drug: ZN-c3
Drug: ZN-d5 ZN-c3

Phase 1, Phase 2

K-Group Alpha

Portland, Oregon, United States and 12 other locations

the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-leukemic activity of WU-NK-101 in R/R AML....

Enrolling
Acute Myeloid Leukemia
Biological: WU-NK-101

Phase 1

Wugen, Inc.

Portland, Oregon, United States and 8 other locations

To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with AML with monocytic differen...

Enrolling
AML With Monocytic Differentiation
CMML
Biological: IO-202 and Azacitidine
Biological: IO-202

Phase 1

Immune-Onc Therapeutics

Portland, Oregon, United States and 13 other locations

\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Fludarabine

Phase 3

LLS PedAL Initiative, LLC

Portland, Oregon, United States and 73 other locations

A study of siremadlin in combination with venetoclax plus azacitidine in adult participants with AML who are ineligible for chemotherapy.The...

Active, not recruiting
Acute Myeloid Leukemia
Drug: siremadlin
Drug: venetoclax

Phase 1

Novartis
Novartis

Portland, Oregon, United States and 9 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Portland, Oregon, United States and 222 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems